Abstract
In order to compare the immunogenicity and safety of different doses of trivalent influenza vaccine (TIV) administered intradermallly (ID) with those evoked by a full dose of intramuscular (IM) virosomal-adjuvanted influenza vaccine (VA-TIV), 112 previously primed healthy children aged ≥3 years were randomised to receive 9 μg or 15 μg of each strain of ID-TIV, or a full IM dose (15 μg of each strain) of VA-TIV. The A/H1N1 and A/H3N2 seroconversion and seroprotection rates were ≥90% and geometric mean titres (GMTs) increased 3.2-14.9 times without any statistically significant between-group differences; however, the seroconversion and seroprotection rates against the B strain were significantly higher in the children receiving either ID-TIV dose (p<0.05) without any differences between them. GMT against B virus was significantly higher in the children receiving the highest dose (p<0.05). Local reactions were significantly more common among the children receiving either ID-TIV dose (p<0.05), but systemic reactions were relatively uncommon in all three groups. Our findings suggest that ID-TIV with 15 μg of each viral antigen can confer a significant better protection against influenza than that obtained with the same dose of IM TIV in already primed children aged ≥3 years with an acceptable safety profile. The lower dose of ID-TIV needs further evaluation to analyze persistence of protection.
| Original language | English |
|---|---|
| Pages (from-to) | 7606-7610 |
| Number of pages | 5 |
| Journal | Vaccine |
| Volume | 29 |
| Issue number | 44 |
| DOIs | |
| Publication status | Published - Oct 13 2011 |
Fingerprint
Keywords
- Children
- Influenza
- Influenza vaccination
- Intradermal influenza vaccine
- Pediatrics
ASJC Scopus subject areas
- Immunology and Microbiology(all)
- Infectious Diseases
- Public Health, Environmental and Occupational Health
- veterinary(all)
- Molecular Medicine
Cite this
Immunogenicity and safety of intradermal influenza vaccine in children. / Esposito, Susanna; Daleno, Cristina; Picciolli, Irene; Tagliaferri, Laura; Scala, Alessia; Prunotto, Giulia; Montinaro, Valentina; Galeone, Carlotta; Principi, Nicola.
In: Vaccine, Vol. 29, No. 44, 13.10.2011, p. 7606-7610.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunogenicity and safety of intradermal influenza vaccine in children
AU - Esposito, Susanna
AU - Daleno, Cristina
AU - Picciolli, Irene
AU - Tagliaferri, Laura
AU - Scala, Alessia
AU - Prunotto, Giulia
AU - Montinaro, Valentina
AU - Galeone, Carlotta
AU - Principi, Nicola
PY - 2011/10/13
Y1 - 2011/10/13
N2 - In order to compare the immunogenicity and safety of different doses of trivalent influenza vaccine (TIV) administered intradermallly (ID) with those evoked by a full dose of intramuscular (IM) virosomal-adjuvanted influenza vaccine (VA-TIV), 112 previously primed healthy children aged ≥3 years were randomised to receive 9 μg or 15 μg of each strain of ID-TIV, or a full IM dose (15 μg of each strain) of VA-TIV. The A/H1N1 and A/H3N2 seroconversion and seroprotection rates were ≥90% and geometric mean titres (GMTs) increased 3.2-14.9 times without any statistically significant between-group differences; however, the seroconversion and seroprotection rates against the B strain were significantly higher in the children receiving either ID-TIV dose (p<0.05) without any differences between them. GMT against B virus was significantly higher in the children receiving the highest dose (p<0.05). Local reactions were significantly more common among the children receiving either ID-TIV dose (p<0.05), but systemic reactions were relatively uncommon in all three groups. Our findings suggest that ID-TIV with 15 μg of each viral antigen can confer a significant better protection against influenza than that obtained with the same dose of IM TIV in already primed children aged ≥3 years with an acceptable safety profile. The lower dose of ID-TIV needs further evaluation to analyze persistence of protection.
AB - In order to compare the immunogenicity and safety of different doses of trivalent influenza vaccine (TIV) administered intradermallly (ID) with those evoked by a full dose of intramuscular (IM) virosomal-adjuvanted influenza vaccine (VA-TIV), 112 previously primed healthy children aged ≥3 years were randomised to receive 9 μg or 15 μg of each strain of ID-TIV, or a full IM dose (15 μg of each strain) of VA-TIV. The A/H1N1 and A/H3N2 seroconversion and seroprotection rates were ≥90% and geometric mean titres (GMTs) increased 3.2-14.9 times without any statistically significant between-group differences; however, the seroconversion and seroprotection rates against the B strain were significantly higher in the children receiving either ID-TIV dose (p<0.05) without any differences between them. GMT against B virus was significantly higher in the children receiving the highest dose (p<0.05). Local reactions were significantly more common among the children receiving either ID-TIV dose (p<0.05), but systemic reactions were relatively uncommon in all three groups. Our findings suggest that ID-TIV with 15 μg of each viral antigen can confer a significant better protection against influenza than that obtained with the same dose of IM TIV in already primed children aged ≥3 years with an acceptable safety profile. The lower dose of ID-TIV needs further evaluation to analyze persistence of protection.
KW - Children
KW - Influenza
KW - Influenza vaccination
KW - Intradermal influenza vaccine
KW - Pediatrics
UR - http://www.scopus.com/inward/record.url?scp=80053588703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053588703&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2011.08.021
DO - 10.1016/j.vaccine.2011.08.021
M3 - Article
VL - 29
SP - 7606
EP - 7610
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 44
ER -